Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mixed Proffered paper and Mini oral session: Gynaecological cancers

287MO - Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive

Date

01 Dec 2023

Session

Mixed Proffered paper and Mini oral session: Gynaecological cancers

Topics

Tumour Site

Ovarian Cancer

Presenters

Somnath Roy

Citation

Annals of Oncology (2023) 34 (suppl_4): S1584-S1598. 10.1016/annonc/annonc1383

Authors

S. Roy1, J. Ghosh2, A. Bhattacharjee1, S. Ganguly3, B. Biswas2, Y.S. Patel4, S. Pal1, J. Karmakar1, D. Mishra5, S. Vinarkar5, I. Dey5, R. Demde5, J. Bhaumik6, A. Ghosh7, B. Chakraborti6

Author affiliations

  • 1 Medical Oncology Department, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 2 Medical Oncology Dept, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 3 Medical Oncology, Tata Medical Center, 700160 - Kolkata/IN
  • 4 Medical Oncology, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 5 Molecular Biology, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 6 Gynac Oncology, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 7 Gynae-oncology, TMC - Tata Medical Center, 700160 - Kolkata/IN

Resources

This content is available to ESMO members and event participants.

Abstract 287MO

Background

Real world Indian data with maintenance Poly ADP Ribose Polymerase 1 Inhibitors (PARPi) in newly diagnosed advanced ovarian cancer (AOC) are lacking. The purpose of this study was to evaluate optimal dosing, safety and efficacy of olaparib or rucaparib maintenance plus minus bevacizumab in germline BRCA mutations or HRD-positive AOC patients.

Methods

This was a retrospective study from Tata Medical Center, Kolkata, West Bengal, India; included patients with stage III & IV (AJCC 7th) AOC between 2020- 2023. All data captured from electronic medical records of hospital up till June 2023. Either standard dose or reduced dose of tablet olaparib (450mg/day orally) or rucaparib (600mg/day orally) plus minus injection bevacizumab (7.5 mg/kg IV q 3weekly) was offered as a front-line maintenance therapy after completion of surgery and platinum based chemotherapy without any residual disease.

Results

Out of 89 screened patients, 41 received therapy with a median age at diagnosis 57 years (range 41-74). 98% had high grade serous histology with 61% stage III and 39% stage IV diseases. 28(68%) patients had germline BRCA mutations and 13(32%) HRD-positive (high genomic scar score). 34(82%) patients received maintenance bevacizumab up to one year along with PARPi. The duration of exposure of PARPi ranged from 2-24 months and 63% patients started with reduced dose. Dose reductions due to adverse effects (AEs) seen in 42%. With a median follow up of 32 months (95% CI 22.04-41.95); two years predicted progression free survival (PFS) of the entire cohort was 84%, no difference in PFS between standard dose and reduced dose group (30 vs 35 months; log rank p=0.67). There was no significant difference in PFS among olaparib and rucaparib (NR vs 35 months; log rank p=0.20). The most common ≥ grade III AEs (CTCAE V.5) were anemia (24%), thrombocytopenia (7%), fatigue (22%), diarrhea (2%) and transamnitis (5%).

Conclusions

We found that lower doses of PARPi were equally efficacious with good tolerance in comparison with standard dose and can be offered as first-line maintenance therapy in AOC patients with germline BRCA mutation or HRD positive in a resource-limited setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.